HIGHLIGHTSResults from the Phase 2a ACCENT trial in pancreatic cancer have been presented at the specialist conference ASCO Gastrointestinal ...

PRINCETON, N. J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Teclison, Inc., a clinical-stage oncology company dedicated to advancing immunotherapeutic treatments for solid tumors, today announced that Ray Lee ...

When combined with the IDO1 inhibitor epacadostat, Keytruda (pembrolizumab), a PD-1 inhibitor, resulted in an overall response rate (ORR) of 35 percent in patients with advanced urothelial carcinoma, ...

The one-and-a-half-day symposium will provide an overview of recent advances in the treatment of solid tumors with novel ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this episode of Meeting Mic, we bring you pearls and ...

Plus Therapeutics will present ReSPECT-LM trial results and host a symposium on leptomeningeal metastases at the SNO/ASCO conference. Announcement of the oral presentation of ReSPECT-LM clinical trial ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients.

ASCO GU 2025 had groundbreaking advancements in genitourinary cancer treatments, focusing on prostate cancer, renal cell ...

BullFrog AI's bfLEAP platform identified biomarkers linked to improved survival in pancreatic adenocarcinoma patients treated ...

Every year when the American Society of Clinical Oncology (ASCO) annual meeting rolls around, thousands of healthcare stakeholders make their way to Chicago to evaluate the future of cancer care. The ...